ocrevus in primary progressive multiple sclerosis 6.5-year data [orotorio extension study]
Published 3 years ago • 5.3K plays • Length 14:19Download video MP4
Download video MP3
Similar videos
-
8:11
ocrevus reduces cane use by 50% in 6-year follow-up data; genentech press release; opera i/ii
-
10:12
progressive multiple sclerosis prognosis explained by neurologist [data from ms base]
-
20:21
spms and ppms are the same (multiple sclerosis is one disease) [neurologist explains]
-
19:29
ocrevus: do you need it every 6 months?
-
6:00
2nd pml case with ocrevus reported by genentech
-
19:10
optimal dose of ocrevus for multiple sclerosis
-
19:30
ocrevus vs. rituximab (neurologist explains observational data)
-
19:54
progressive multiple sclerosis treatments
-
11:56
colitis with ocrevus & rituximab
-
11:11
tysabri vs ocrevus. which is better?
-
4:14
ocrevus pml case update
-
3:21
new data support benefit of ocrevus for relapsing, primary progressive multiple sclerosis
-
16:47
is hsct for ms overrated? [neurologist reviews data vs. tysabri, ocrevus, and gilenya]
-
14:28
risk of b-cell depleters long-term (ocrevus, rituximab, kesimpta, briumvi)
-
10:32
ocrevus side effects explained by neurologist
-
25:00
hsct vs tysabri , ocrevus, and gilenya in observational study explained by neurologist
-
6:12
pml in patient taking ocrevus!
-
33:29
multiple sclerosis overview 2024
-
5:33
neurologist tries multiple sclerosis meds!